Background In real-world practice settings, there is insufficient evidence on the efficacy of
antiplatelet drugs, including clopidogrel, aspirin, and ticlopidine, in stroke prevention …

Background Clopidogrel was thought to be superior to aspirin for secondary prevention of
vascular diseases in clinical trials. In this study we assessed the safety and efficacy of …

Background Several clinical trials reported that clopidogrel was superior to aspirin in
secondary stroke prevention by reducing the risk of major adverse cardiovascular events …

Background In patients with ischemic stroke of non-cardioembolic origin, acetylsalicylic acid,
clopidogrel, or a combination of acetylsalicylic acid and dipyridamole are recommended for …

Background: The current study compared the efficacy and safety of clopidogrel vs aspirin in
the secondary prevention of ischemic stroke (IS). Methods: We included patients from the …

OBJECTIVE: To review and summarize the efficacy, mechanisms of action, and cost of the
options available when choosing antiplatelet agents for secondary stroke prevention. DATA …

Stroke is the third leading cause of death in the United States. Antiplatelet agents are the
mainstays of ischaemic stroke prevention. The therapies recommended for initial therapy …

Background: Antiplatelet agents are the mainstay for secondary prevention of non-
cardioembolic stroke. This systematic review examined the safety and efficacy of short …

Patients with transient ischemic attack (TIA) or ischemic stroke carry a risk of recurrent stroke
of between 5% and 20% per year. In patients with TIA or ischemic stroke of non-cardiac …

Network meta-analysis is a fairly new method for assessing the relative effectiveness of two
treatments when they have not been directly evaluated in a controlled randomized trial …